Vaccine Market 2022-2027: Growth Analysis, Size, Share, Trends and Forecast

According to the latest report by IMARC Group, titled “Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global vaccine market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global vaccine market is expected to exhibit a CAGR of 10.33% during 2022-2027. A vaccine refers to a biological element that stimulates the production of antibodies against pathogens present in the body. It is generally created by using disease-causing agents and chemical drugs that act as antigens in illness prevention. Vaccines are mainly available in the form of conjugate, inactivated, live attenuated, recombinant, subunit, and toxoid. They aid in preventing various life-threatening diseases, including polio, diphtheria, meningitis, influenza, measles, tetanus, rotavirus, hepatitis, etc. As a result, vaccines find widespread applications in several immunization procedures across clinics, hospitals, and vaccination centers and for research purposes in academic laboratories.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Sample Report: https://www.imarcgroup.com/vaccine-market/requestsample

Global Vaccine Market Trends and Drivers:

The escalating prevalence of various contagious diseases and the increasing consumer awareness towards adequate immunization for eradicating infections are among the primary factors driving the vaccine market. Besides this, the launch of several policies by the government bodies to promote vaccination programs, especially across endemic regions, is further augmenting the market growth. Moreover, the development of new and improved vaccines by the leading pharmaceutical companies by accelerating the clinical trials of various pipeline drugs is also catalyzing the global market.

Apart from this, the rising number of child deaths, owing to several chronic diseases, such as hepatitis, polio, measles, rubella, etc., particularly across the under-developed countries, are acting as significant growth-inducing factors. Additionally, the growing involvement of international organizations across the globe, including WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation, etc., in designing adequate vaccination facilities is also stimulating the market growth. Furthermore, the extensive research and development (R&D) activities to immunize various fatal conditions, such as AIDS, Ebola, Hepatitis C, paratyphoid fever, etc., are anticipated to propel the vaccine market over the forecasted period.

Key Market Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

• Abbott Laboratories (NYSE: ABT)
• Astellas Pharma Inc. (OTCMKTS: ALPMY)
• AstraZeneca Plc (NASDAQ: AZN)
• Bharat Biotech International Limited
• Bavarian Nordic A/S (OTCMKTS: BVNRY)
• CSL Limited (OTCMKTS: CSLLY)
• Daiichi Sankyo Company, Limited (OTCMKTS: DSNKY)
• Emergent BioSolutions Inc. (NYSE: EBS)
• GlaxoSmithKline Plc (NYSE: GSK)
• Inovio Pharmaceuticals Inc. (NASDAQ: INO)
• Johnson & Johnson, Inc. (NYSE: JNJ)
• Merck & Co. Inc. (NYSE: MRK)
• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
• Novavax Inc. (NASDAQ: NVAX)
• Panacea Biotec Ltd. (NSE: PANACEABIO)
• Pfizer Inc. (NYSE: PFE)
• Sanofi Pasteur SA (Sanofi SA) (NASDAQ: SNY)
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited (NYSE: TAK)

Breakup by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Breakup by Patient Type:

• Paediatric
• Adult

Breakup by Indication:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others

Breakup by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

Breakup by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine

Breakup by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine

Breakup by End User:

• Hospitals
• Clinics
• Vaccination Centres
• Academic and Research Institutes
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the Report:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

TOC for the Report:

• Preface
• Scope and Methodology
• Executive Summary
• Introduction
• Global Market
• SWOT Analysis
• Value Chain Analysis
• Price Analysis
• Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group          
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800